BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) will present two oral presentations and three posters on new acoramidis data in transthyretin amyloid cardiomyopathy (ATTR-CM) at the ESC Congress 2026 in Munich on August 28–31, 2026. These include open-label extension analyses from the ATTRibute-CM study, covering survival, hospitalization days, myocardial structure/function, and patient-reported outcomes in wild-type and variant ATTR-CM.

In partnership with Yale’s Cardiovascular Data Science Lab, three additional moderated ePosters will highlight AI-driven approaches for ATTR-CM, including a digital biomarker AI-ECG, a decentralized digital registry, and a nationwide multimodal screening network. Acoramidis is marketed as Attruby and BEYONTTRA, indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM. Diarrhea and upper abdominal pain were the most common adverse reactions versus placebo, with similar discontinuation rates.

Market Context

BBIO's active resale registration covers 24,628,286 shares. That platform context places the present...

Analysis

BBIO's active resale registration covers 24,628,286 shares. That platform context places the presentation announcement alongside an existing resale overhang; recent Net Selling insider activity is a separate risk factor to monitor.

Key Figures

Presentations: 2 oral presentations; 3 posters Congress dates: August 28-31, 2026 TTR stabilization: ≥90% +5 more

8 metrics

Presentations 2 oral presentations; 3 posters ESC Congress 2026

Congress dates August 28-31, 2026 Munich, Germany

TTR stabilization ≥90% Acoramidis mechanism

Follow-up period 54 months ATTRibute-CM and open-label extension

Diarrhea 11.6% vs 7.6% Attruby versus placebo

Upper abdominal pain 5.5% vs 1.4% Attruby versus placebo

Discontinuation due to adverse events 9.3% vs 8.5% Attruby versus placebo

Trial design Phase 3 Pivotal randomized controlled trial

Historical Context

5 past events · Latest: Aug 14 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Secondary offering	Negative	-1.7%	KKR sold 5,000,000 existing shares in a secondary transaction without BridgeBio proceeds.
Aug 13	Secondary offering	Negative	-1.7%	KKR launched a 5,000,000-share secondary offering with no company proceeds.
Aug 11	Inducement grants	Positive	+0.1%	The board approved equity grants covering 66,705 shares for 56 new employees.
Aug 10	Quarterly earnings	Positive	-1.1%	Second-quarter revenue reached $243.7 million, but the 24-hour reaction was negative.
Aug 03	Earnings scheduling	Neutral	-0.2%	BridgeBio scheduled second-quarter results and its business update for August 10.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BBIO's recent negative offering announcements aligned with declines, whereas the positive earnings event diverged with a negative reaction.

Key Terms

open-label extension, eq-5d-5l, randomized controlled trial, digital biomarker

4 terms

open-label extension medical

"Interim Findings from ATTRibute-CM and its Open-Label Extension"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

eq-5d-5l medical

"An EQ-5D-5L Subgroup Analysis from ATTRibute-CM"

A standardized questionnaire that measures a patient's health across five areas — mobility, self-care, usual activities, pain/discomfort and anxiety/depression — using five levels of severity. Think of it as a concise health “report card” that converts how patients feel into a single score; investors use those scores to judge how much a treatment or product improves quality of life, informs pricing, reimbursement and market potential.

randomized controlled trial medical

"within a Phase 3 Pivotal Randomized Controlled Trial"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

digital biomarker technical

"A Novel AI-Derived Digital Biomarker for Monitoring Disease Progression"

A digital biomarker is measurable health information captured by sensors, apps, or wearable devices—such as heart rate patterns, walking speed, or sleep activity—that acts like a dashboard light indicating a person’s physical or mental condition. Investors care because these signals can speed drug development, enable new monitoring services, and create recurring data-driven revenue, while also carrying regulatory and validation risks that affect commercial and clinical value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

As part of BridgeBio's partnership with Yale's Cardiovascular Data Science (CarDS) Lab to advance AI networks for earlier detection of ATTR-CM, three additional posters will be presented at the ESC Congress 2026.

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Oral Presentations:
Acoramidis Reduces Days Lost to Death and/or Cardiovascular-Related Hospitalization, Preserving Time Alive Outside the Hospital in Participants with ATTR-CM: Results from ATTRibute-CM
Presenter: Richard Wright, M.D., Pacific Heart Institute, U.S.
Date: Sunday, August 30 at 8:15 am CEST

Durable Survival Benefits of Acoramidis over 54 Months in Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Including p.V142I: Interim Findings from ATTRibute-CM and its Open-Label Extension
Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, U.S.
Date: Sunday, August 30 at 10:55 am CEST

Moderated ePosters:
Long-term Improvement in Myocardial Structure and Function in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treated with Acoramidis Compared with a Natural History Cohort
Presenter: Awais Sheikh, MBChB, National Amyloidosis Centre, London, UK
Date: Friday, August 28 at 4:15 pm CEST

Acoramidis Improves Health-Related Quality of Life in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: An EQ-5D-5L Subgroup Analysis from ATTRibute-CM
Presenter: Emer Joyce, M.D., Ph.D., The Mater Misericordiae University Hospital, IE
Date: Sunday, August 30 at 3:15 pm CEST

Improvement of Health Status with Acoramidis in Patients with Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: KCCQ Domains Analysis from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D., University of Chicago Medical Center, U.S.
Date: Sunday, August 30 at 3:15 pm CEST

Yale-Partnered Moderated ePosters:
A Novel AI-Derived Digital Biomarker for Monitoring Disease Progression in ATTR-CM: First-In-Trial Use of a Computer Vision AI-ECG Algorithm within a Phase 3 Pivotal Randomized Controlled Trial
Presenter: Rohan Khera, M.D., Yale School of Medicine, U.S.
Date: Monday, August 31 at 11:15 am CEST

A Fully Decentralized, Patient-Led Digital Registry for ATTR-CM Integrating Multisystem EHR and Wearable Data: The DISCOVER-ATTR Study
Presenter: Aline Pedroso, Ph.D., Yale School of Medicine, U.S.
Date: Monday, August 31 at 1:15 pm CEST

Nationwide U.S. Federated Deployment of Artificial Intelligence for Multimodal Screening of ATTR Cardiomyopathy: First Multicenter Analysis from the TRACE-AI Network
Presenter: Bruno Batinica, MBChB, Yale School of Medicine, U.S.
Date: Sunday, August 30 at 1:35 pm CEST

About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com 

FAQ

What ATTR-CM data on acoramidis will BridgeBio (BBIO) present at ESC Congress 2026?

BridgeBio will present two oral presentations and three posters on new acoramidis data in ATTR-CM. According to BridgeBio, these include open-label extension analyses from ATTRibute-CM on survival, hospitalization days, myocardial structure/function, and health-related quality-of-life outcomes in wild-type and variant ATTR-CM.

When and where is BridgeBio presenting acoramidis ATTRibute-CM results at ESC Congress 2026?

BridgeBio-associated presentations will occur August 28–31, 2026, at ESC Congress 2026 in Munich, Germany. According to BridgeBio, key oral sessions are scheduled for Sunday, August 30, including data on days lost to death or cardiovascular hospitalization and 54‑month survival in variant ATTR-CM.

What is the approved indication for Attruby (acoramidis) in ATTR-CM patients?

Attruby is indicated as a transthyretin stabilizer to treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults. According to BridgeBio, it is approved to reduce cardiovascular death and cardiovascular-related hospitalization in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM).

What are the main side effects of Attruby (acoramidis) reported by BridgeBio?

The most common adverse reactions with Attruby were diarrhea and upper abdominal pain, occurring more often than with placebo. According to BridgeBio, most events were mild, resolved without discontinuation, and discontinuation rates due to adverse events were similar between Attruby and placebo groups.

How is BridgeBio using artificial intelligence for earlier detection of ATTR-CM?

BridgeBio is partnering with Yale’s Cardiovascular Data Science Lab on several AI initiatives for ATTR-CM. According to BridgeBio, ESC Congress 2026 posters will cover an AI‑ECG digital biomarker, a decentralized digital registry integrating EHR and wearables, and a nationwide multimodal screening network.

Under what brand names is acoramidis (Attruby) approved globally for ATTR-CM?

Acoramidis is marketed as Attruby in the United States and as BEYONTTRA in several other regions. According to BridgeBio, it is approved by the EMA, Japanese, Swiss, UK, and Brazilian regulators, with labels specifying near-complete transthyretin stabilization.